中药降尿酸方治疗高尿酸血症的疗效:双盲非劣效随机对照临床试验研究方案
本研究为双盲非劣效随机对照试验,计划纳入72例高尿酸血症患者,按1:2随机分为非布司他40 mg组(WG组,n=24)和降尿酸方+非布司他20 mg组(WJNSG组,n=48)。12周后WJNSG组再随机分为继续降尿酸方+非布司他20 mg组(WJNSG组,n=24)和降尿酸方+安慰剂组(JNSG组,n=24),每4周随访。主要结局为血清尿酸水平变化,次要结局为中医证候积分变化。
要点
- 降尿酸方在中国常用于治疗高尿酸血症,但缺乏研究证据支持其使用。
- 本试验采用双盲非劣效设计,主要结局为血清尿酸水平变化。
- 次要结局包括中医证候积分变化,同时检测血清肌酐、血糖和胰岛素水平。
核心结论
- 研究者假设高尿酸血症患者可从降尿酸方中获益,本研究将为临床医生提供循证推荐。
研究设计与样本
- 双盲非劣效随机对照临床试验,计划纳入72例高尿酸血症患者,按1:2随机分为WG组(非布司他40 mg,n=24)和WJNSG组(降尿酸方+非布司他20 mg,n=48)。
- 12周后WJNSG组随机分为两组各24例:WJNSG组(非布司他20 mg+降尿酸方)和JNSG组(降尿酸方+安慰剂)。
- 每4周随访一次。
关键数值与推荐
- 主要结局为血清尿酸水平变化。
- 次要结局为中医证候积分变化。
- 同时检测血清肌酐、血糖和胰岛素水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Jiangniaosuan formula (JNSF) is commonly used in China for treating hyperuricemia, but there is little research-based evidence to support its use. This randomized controlled trial aims to assess the efficacy and safety of JNSF. METHODS: A total of 72 patients with hyperuricemia will be selected and randomly assigned in a ratio of 1:2 to receive either Western medicine, i.e., febuxostat 40 mg (WG group; n = 24), or Chinese herbal medicine, i.e., Jiangniaosuan formula + febuxostat 20 mg (WJNSG group; n = 48). After 12 weeks, the WJNSG will be randomly divided into two groups of 24 patients each; one group (WJNSG; n = 24) still will receive febuxostat 20 mg + Jiangniaosuan formula, and the other group (JNSG; n = 24) will continue to receive Jiangniaosuan formula + placebo. Participants will be followed up at 4-week intervals. The primary outcome will be the change in serum uric acid level, and the secondary outcome will be the change in traditional Chinese medicine (TCM) syndrome scores. Serum creatinine, blood glucose, and insulin levels will also be measured. DISCUSSION: We hypothesize that patients with hyperuricemia will benefit from JNSF. This study will provide evidence-based recommendations for clinicians. DISSEMINATION: The results will be published in a peer-reviewed journal and disseminated by academic conferences. The datasets analyzed during the current study are available from the corresponding author on reasonable request. TRIAL REGISTRATION: Chinese Clinical Trials Register ChiCTR2000041083 . Registered on 3 May 2021. The protocol version number is V3.0, 20210301.
引用
- Guo Y, Lu H, Gan J, et al. Efficacy of Chinese herbal medicine Jiangniaosuan formula for treatment of hyperuricemia: study protocol for a double-blinded non-inferiority randomized controlled clinical trial. Trials. 2022. PMID: 34980237. doi:10.1186/s13063-021-05959-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。